Background: ABT-494 is a selective Janus Kinase 1 inhibitor currently being evaluated in Phase 3 trials for treatment of rheumatoid arthritis (RA) at doses of 15 mg and 30 mg once daily using the extended-release tablet formulation. Exposure-response analysis of ECG data collected at early stage clinical trials has been recently adopted in regulatory guidelines as a tool to assess the proarrhythmic risk of investigational new drugs. Objectives: The objective of this work was to evaluate ABT-494 QT prolongation potential using exposure-response analysis of data collected in early Phase 1 studies. Methods: Doses of ABT-494 or placebo were administered to healthy subjects in two Phase 1 studies. Evaluated ABT-494 immediate-release regimens ranged from 1 mg to 48 mg single doses under fasting conditions and 3 mg to 24 mg twice daily under non-fasting conditions. Serial triplicate electrocardiograms and pharmacokinetic assessments were conducted. The relationship between change from baseline in Fridericia-corrected QT interval (QTcF) and ABT-494 plasma concentrations was characterized using linear mixed-effects modeling. To evaluate the ECG assay sensitivity, the change in QTcF from baseline to 2 hours post-dose was compared for subjects who received placebo under fasting and non-fasting conditions. Results: There was no statistically significant relationship between the change from baseline in the QTcF interval and ABT-494 plasma concentrations. The point estimate of the effect on QTcF for the highest concentration observed in the evaluated studies, which is approximately 4-fold higher than the mean C max of the highest RA Phase 3 dose, is -1.77 msec (with upper bound of the 95% one-sided confidence interval of 3.33 msec; lower than the regulatory threshold of concern of 10 msec). Food shortened the QTcF interval by 5.9 msec (2-sided 90% confidence interval of -9.6 to -2.1 msec), indicating that the ECG assay used in the studies had adequate sensitivity to detect the small change in QTcF caused by food. Conclusions: ABT-494 showed no potential for QT prolongation at the expected therapeutic and supra-therapeutic plasma exposures for the doses being used in Phase 3 RA trials. Background: Lesion of the cardiovascular system is associated with uncontrolled inflammation and immune defects in patients with Rheumatoid Arthritis (RA). There is an evidence of the close pathogenetic connection between rheumatoid inflammation and accelerated development of atherosclerosis. The first sing of atherosclerosis is endothelial dysfunction (ED). Objectives: Evaluate the effectiveness of NO donators (4,2% solution of arginine hydrochloride and L-arginine aspartate) in the correction of lipid and ED in patients with RA and secondary Raynaud's syndrome (RS). Methods: 68 patients with RA were examined. All patients were divided into 2 groups: (37 people with RA in combination with secondary RS) received basic therapy of RA (methotrexate 10-15 mg/wk.), antiplatelet and vasodilatory drugs; II group (31 people -RA in combination with secondary RS) got similar therapy plus NO donators (4,2% solution of arginine hydrochloride and L-arginine aspartate). The examination was carried out at the patient's admission to the hospital and the hospital and 3 months after the beginning of treatment. Endothelial function was assessed by determining the flow-mediated vasodilation of brachial artery (FMD), levels of endothelin-1, rheumatoid factor (RF), C-reactive protein (CRP), lipid profile (total cholesterol -TC, low density lipoprotein -LDL, highdensitylipoprotein -HDL and triglycerides -TG), index of intima/media (IM) and atherogenic index (AI). Results: Levels of TC, LDL, AI and MI indexes were significantly higher than the norm in 2 compared groups before the treatment and 3 months after its start (p<0,05). There were significant decreases in levels of lipid profile, IA and MI index in II group 3 months after treatment in comparison to benchmarks (TC by 13,3%, LDL by 16,1%, TG by 14,7%, AI index by 13,8% MI index by 12,7%,p<0,05) and they were significantly unchanged in I group (p<0,05). It was elucidated a direct reliable strong correlation in patients of II group between the level of FMD and endothelin-1 before treatment (r=0,73, p<0,05) and after treatment (r=0,69, p<0,05). Symptoms of ED, levels of endothelin-1, RF, CRP were decreased in patients of both groups after the conducted therapy. It was established a proportionately reliable correction between CRP and LDL levels after treatment in II group of patient (r=0,63, p<0,05). Conclusions: 1.There is a lack of flow-mediated vasodilation of brachial artery in patients with RA and secondary RS, which can indicate a dysregulation of endothelial function. 2. The level of CRP is increased in patients with RA and secondary RS and is associated with the risk of hyperlipemia and atherosclerosis. 3. The usage of NO donators (4,2% solution of arginine hydrochloride and L-arginine aspartate) in the treatment of RA with secondary RS significantly reduces the levels of IA and IM index, the level of atherogenic lipoprotein fractions (TC, LDL and TG) and decreases the severity of ED, which leads to minimizing the risk of atherogenesis and its complications. Background: Tofacitinib is a new small molecule, Janus kinase 1 and 3 inhibitor, interfering with the JAK-STAT signaling pathway. The JAK-STAT transmits the extracellular information in the cell nucleus, influencing DNA transcription. Its efficacy and safety in Rheumatoid Arthritis (RA) has been demonstrated in different phase II, III and long-term clinical studies. It has been approved in Argentina for the treatment of patients with moderate to severe rheumatoid arthritis RA with failure to conventional DMARDs. Objectives: To communicate real world safety data from patients with RA under treatment with Tofacitinib. Methods: A retrospective, descriptive study from patients with RA (ACR/ EULAR2010) under treatment with Tofacitinib from September 2014 to December 2016 was conducted. Medical records from patients being treated with Tofacitinib were reviewed and demographic data were recorded. Comorbidities, concomitant treatments, and reported adverse effects were documented. Results: 62 patients were treated with Tofacitinib. 53 were female and 9 were male, with a mean age of 57.91±14.72 years and average disease duration of 140.09±130.83 months. 18 patients (29%) had at least one comorbidity, the most frequent being hypertension (77%). Of the 62 patients studied, 54 (87%) had established RA (duration of illness greater than 24 months) and 8 patients (13%) with early RA (less than 24 months). In 54 patients Tofacitinib was indicated in combination with another DMARD (87%), and only 6 patients received treatment as monotherapy. The most commonly used DMARD in combination therapy was methotrexate (MTX) in 92.5% Treatments were indicated by failure to MTX or other conventional DMARDs, 12/62 treatments were indicated by failure to treatment with 1 biological DMARD and 13/62 treatments were indicated by failure to two or more biological DMARDs. The maximum exposure time was 21 months. During the time of exposure to Tofacitinib the following adverse events were observed: Herpes Zoster infection 2 cases (monometameric, no visceral involvement in unvaccinated patients), upper airway infection 1 case, transient increase in liver enzymes 1 case, peripheral facial paralysis 1 case, tachycardia 1 case. There were no cases of serious infections, opportunistic infections, cytopenias, dyslipidemia, or increased CPK. Three patients discontinued Tofacitinib: one due to tachycardia, another case peripheral facial paralysis and another case due inefficacy. Conclusions: Most patients received combined treatment with DMARDs being the most commonly used Methotrexate. There were no cases of serious infections, opportunistic infections, cytopenias or dyslipidemia. The use of Tofacitinib in RA patients in our cohort showed a comparable safety profile with long-term extension studies in the treatment of patients with RA diagnosed with failure of conventional or biological DMARDs. Background: It is known that the early period of rheumatoid arthritis (RA) has a critical role in the development and progression of immune inflammation. Allocation of early RA is due to the need for timely appointment of basic anti-inflammatory drugs to prevent the development of destructive changes in the joints and improve its current forecast. We have proposed a combination of two basic drugs for the treatment of RA, methotrexate (MTX) and leflunomide (LF). While this combination, we proceeded from the basic principles of combination therapy: each of the drugs has an independent clinical effect in early RA, the drugs have different mechanisms of action and different spectrum of side effects. Objectives: Investigating of clinical efficacy of combination therapy with MT and LF in patients with RA in its early stages Methods: We observed 80 patients with early RA, 50 patients of them were women and 30 patients were male. The age of patients ranged from 24 up to 42 years old (31,7±7,6), the duration of illness was 6 months. Activity of RA was corresponded to the II degree (DAS 28 <4.7) in 48 patients, III degree (DAS28>5,1) was in 32 patients. 1st group consisted of 40 patients and the 2nd group involved 40 patients. Patients in 1st group received combination therapy with LF in doses 20 mg/day and MT in doses 7.5 mg/week. 2nd group received just MT as a single basic anti-inflammatory drug in doses 7.5 mg/week. In order to improve portability of MT was administered to all patients folic acid in doses 1.2 mg/day, 5 days in a week. The efficiency of the intervention was evaluated after 6 months by reducing of the final value of the indicator of inflammatory activity. Results: The results of observation of patients for 6 months were showed that, combination therapy with MT and LF provides a quick and pronounced clinical effect in patients in the early stages of RA. Patients of 1st group according to criteria ACR 50-70% improvement was achieved in 50% of patients, while figure of all indicators of patients in 2nd group was 33.4%. During the treatment was indicated improvement of laboratory parameters of disease activity of RA in both groups, features of activity of 1st group were decreased up to (DAS28 =2,9), signs of 2nd group were (DAS28 =3,6). However, there were 26% of cases of clinical remission of the disease in patients of 1st group than patients of 2nd group. Known side effects of combination therapy with MT and LF in most cases have not been severe, reversible and demanded the abolition of drugs in rare (11.2%) cases. Conclusions: Combined basic therapy of patients in the early stages of RA with LF and MT has more efficiency than mono therapy. Disclosure of Interest: None declared DOI: 10.1136/annrheumdis-2017-eular.4770 
